Meilleur Technologies Inc. Announces Use of the Next-Generation Amyloid PET Imaging Biomarker, NAV-4694, in the NIA-sponsored CLARiTI Trial

2023-11-06
临床研究
KNOXVILLE, Tenn.--(BUSINESS WIRE)-- Meilleur Technologies, Inc. today announced a research collaboration agreement with the National Institute on Aging (NIA)-sponsored multicenter study called the Consortium for Clarity in ADRD Research Through Imaging (CLARiTI). The collaboration will involve the network of Alzheimer’s Disease Research Centers across the country (currently, there are 37 centers of excellence), will recruit 2000 subjects, and apply cutting-edge imaging and blood-based biomarkers to investigate the multiple intersecting neurodegenerative causes of cognitive impairment (known collectively as Alzheimer’s disease and related disorders or ADRD). Sterling Johnson, the CLARiTI STUDY Lead, stated: “A major gap in our field is the ability to detect and develop a temporal pro the several pathologies that may be present in our older patients with cognitive symptoms. This requires a broad panel of biomarkers. The partnership with Meilleur will enable accessible state of the art amyloid PET imaging, which we believe is foundational to further discovery.” “Meilleur is focused on enabling access to key technologies such as NAV-4694, a highly sensitive molecular imaging tool, with the aim to better understand disease and ultimately support the acceleration of drug development in neurodegenerative disorders,” said Samantha Budd Haeberlein, Chief Medical Officer, Meilleur Technologies, Inc. “The NIA-sponsored CLARiTI study will provide critical data on early amyloid deposition across a large population with Alzheimer’s disease and related disorders. We applaud the NIA and the ADRC for their initiative.” About Meilleur Technologies, Inc. Meilleur’s vision is to develop diagnostics and technology that positively impact patients with neurodegenerative disorders, including Alzheimer’s disease.
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
靶点
-
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。